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Abstract
Background: Asthma and chronic obstructive pulmonary disease (COPD) are disorders of the lungs characterized
by airflow obstruction, inflammation and tissue remodeling. Management of patients with these diseases is complex
and the improvement of diagnostic-therapeutic strategies represents a critical challenge for the healthcare system. In
this context, investigating the criteria and information needed for an appropriate and effective evaluation of incoming
treatment options is crucial to ensure that clinicians and policy-makers are provided with the best available evidence to
make decisions aimed at improving patient outcomes. Therefore, the objective of this study was to investigate the
degree of agreement among Health Technology Assessment (HTA) experts on issues crucial to the evaluation of new
drugs for asthma and COPD and to appropriately manage the clinical pathway for patients.
Method: This research was conducted using an e-Delphi technique organized in three subsequent rounds and involving
a panel of ten experts (six regional and local payers and four clinicians). Panelists were asked to comment in written form
on a set of statements, explaining qualitatively the extent to which they agreed or disagreed with the assertions.
Statements were subsequently modified and resubmitted for assessment.
Results: Panelists expressed their opinions during each round and, after round III, a consensus document was finalized.
The degree of consensus was high among experts and concerned five main topics: (a) the need to address current
unmet needs of patients with asthma or COPD, (b) the importance of further studies and real-life information in the
evaluation of treatments, (c) existing evidence and evidence needed to assess drugs, (d) critical issues in obtaining a
positive evaluation from regional and local authorities for new treatments to be included in regional formularies and to
have an important place in therapeutic categories, and (e) the major obstacles to the appropriate administration of
drugs and management of patients.
Conclusion: The final document highlights that no proof of difference among drugs exists, that evidence on final
endpoints (and particularly on mortality) should be strengthened and that actions regarding risk factors, appropriate
diagnosis, patient staging and adherence to therapy are particularly important for a better clinical management.
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Background
Asthma and chronic obstructive pulmonary disease (COPD)
are disorders of the lungs characterized by airflow obstruc-
tion, inflammation and tissue remodeling. Although these
diseases represent a major health problem, they are still
largely underdiagnosed and undertreated [1].
Recent estimates suggest an asthma prevalence of 6.9 %
in the Italian population, with an increasing pattern in re-
cent years [2]. Approximately 3 % of the Italian population
had COPD in 2011 [3], which according to the technical-
scientific Agency of the Italian National Health Services
(Agenas) is likely to underestimate the magnitude of the
phenomenon [4]. According to the World Health
Organization (WHO), the total number of COPD-related
deaths is projected to increase by more than 30 % over the
next 10 years [5].
In addition to the increasing epidemiological burden
of the disease, the management of affected patients is
complex; improving diagnostic-therapeutic pathways
represents a challenge for the healthcare system [6–8].
Identifying the most critical points in the clinical path-
way and the extent to which the system can be improved
are, therefore, fundamental issues on which experts must
reach consensus. Moreover, investigating the criteria and
information needed for an appropriate and effective
evaluation of incoming treatment options is crucial to
ensure that clinicians and policy-makers are provided
with the best available evidence in order to make deci-
sions aimed at improving patient outcomes.
The primary objective of this study was to investigate
the degree of agreement and collect the opinions of a
panel of experts about a selection of issues crucial to the
evaluation of new treatments for patients with asthma
and COPD. Specifically, the statements focused on crit-
ical aspects of the diagnostic phase of these diseases,
correct disease staging, role of real life evidence, boost-
ing patient compliance to treatments and transferability
of study results in national contexts.
Method
The study utilized a Delphi methodology, a technique
used to facilitate information-gathering and communica-
tion on complex issues [9]. As presented in the literature,
the process was characterized by three aspects: anonymity
of study participants during the process, in order to avoid
influences within the group; iteration, to allow participants
to change their opinion from one round to another; and
controlled feedback, meaning that panelists were provided
with the results of previous rounds [10–13].
For the purposes of this study, an e-Delphi technique (e-
mail based; [14, 15]) consisting of three rounds and involv-
ing a panel of ten experts was employed. Experts were
selected on the basis of their expertise in the processes of
HTA evaluation of new treatments for asthma and COPD.
Their professional roles varied from institutional and man-
agerial to clinical: three experts represented regional-level
healthcare authorities, three panelists worked for local
health authorities, and four were clinical experts, some with
roles in national scientific societies. We excluded represen-
tatives of the National Drugs Agency (Agenzia Italiana del
Farmaco-AIFA) from the panel of experts, because (i) AIFA
negotiates price and reimbursement and is less involved in
governing and managing clinical pathways, (ii) new drugs’
price and reimbursement criteria and information sources
are set by law [16], and (iii) regional governments and local
authorities are the actual payers.
Panelists were asked to comment on a set of eight state-
ments presented in a .docx document (Italian language),
explaining in a qualitative way the extent to which they
agreed or disagreed with the assertions. Statements were
subsequently modified to incorporate comments, and re-
submitted for assessment to each of the panelists independ-
ently. As suggested by Keeney et al. [14], similar statements
were reduced to a single encompassing statement, main-
taining the original wording to the extent possible. In case
of contrasting opinions, both views were reported in the
statement specifying that panelists differed in their views
on that specific assertion. The statements reported in this
document are, therefore, not the original ones submitted
for panelists’ comment but the final statement on which ex-
perts intervened and finally reached consensus on.
The original statements were constructed following a
non-systematic review of the literature regarding two is-
sues that are particularly critical for the stakeholders:
evaluation of drugs by Italian HTA agencies and imple-
mentation of diagnostic-therapeutic pathways in the Ital-
ian National Health Service (NHS). The role of clinical
pathways in the field of asthma and COPD has been
widely recognized as crucial for improving patient out-
comes [17, 18] and this is particularly relevant in the Ital-
ian context, where the importance of diagnostic-
therapeutic paths as a tool to ensure application of clinical
guidelines [19, 20]) has received extensive attention. To
this end, the analysis of issues around the definition of
care pathways we conducted in this study represents an
important step toward compliance with international
guidelines. Moreover, analyzing and promoting discussion
over criteria and evidence deemed necessary by payers to
evaluate new treatments is crucial to balance increasingly
scarce resources with the sustainability of clinical path-
ways [21]. Therefore, statements were also included to ad-
dress this issue from the perspective of Italian payers.
Results
The process toward consensus was fluid, as no major
disagreement was encountered since the first round.
Comments by panelists mostly added complementary in-
formation to the statements provided or helped in
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clarifying the statements. For example, one panelist stressed
the importance of primary prevention, which was not in-
cluded in the first document draft; all responders then
agreed to include actions aimed at reducing risk factors as a
priority. Consensus was reached on eight statements
encompassing five main topics: unmet needs of patients
with asthma or COPD, criteria for the evaluation of new
treatments, existing evidence and evidence needed to assess
drugs, critical issues in obtaining a positive evaluation from
regional and local authorities for new treatments to be in-
cluded in the regional formularies, and obstacles for the ap-
propriate administration of drugs. Prevention, diagnosis and
staging of patients were identified as critical points of the
clinical pathway, which should be addressed by further ac-
tions aimed at educating patients and clinicians, collection
and analysis of relevant population data, and at promoting
adherence to guidelines. Existing and desirable evidence re-
garding therapeutic treatments was discussed, emphasizing
the importance of real-life information for these complex
diseases. Adherence to therapy was also highlighted as a
crucial area in which improvement is needed.
The document presented to panelists had a ‘Background’
section, introducing key data on the two diseases and some
of the relevant drugs currently reimbursed in Italy (see list
in Additional file 1). A second section included the eight
statements and some contextualization remarks. This sec-
tion reported the English translation of the final consensus
document on the statements reached after round III. Pan-
elists expressed their opinions in each round and, after
round III, a consensus document was finalized, incorporat-
ing changes to the original document.
Delphi document – final version
According to the literature, asthma and COPD are often
underdiagnosed [1, 22]. This is mainly due to three factors:
i) the chronic and recurrent nature of these diseases requires
a careful monitoring of patients to detect arising symptoms;
ii) COPD is characterized by a discrepancy between symp-
toms and the degree of airflow obstruction; and iii) patients
tend to get accustomed to symptoms, adapting their lifestyle
to their new health status. Failure to recognize the symp-
toms of these diseases is therefore frequent among patients.
For instance, COPD symptoms are sometimes mistakenly
interpreted as asthma symptoms at the time of diagnosis
[23–25]. As outlined by National Institute for Health and
Care Excellence (NICE), it should be considered that the
process of diagnosis for asthma differs in adults and children
and also varies among adults and among children [26].
Inappropriate diagnosis and, consequently, inappropriate
treatment, entails significant costs for the healthcare sys-
tem. In particular, significant expenditures occur due to
hospitalization [24, 27] and indirect costs in the form of
“presenteeism” (presence at the workplace when sick) [28].
Given these findings we can state that:
A correct staging of the diseases is needed to define
the appropriate therapeutic scheme [29, 30]. Considering
this, we can state that:
With respect to the available pharmaceutical options,
a recent systematic review has demonstrated a substan-
tial comparability of the efficacy of aclidinium bromide,
tiotropium bromide and glycopyrronium bromide as
maintenance therapy for COPD [32]. A second, less re-
cent systematic review by Shepherd et al. [33] on the
comparative efficacy of different inhaled corticosteroids
in association with different long-acting beta-2 agonists,
indicated a substantial similarity of the efficacy between
these asthma treatments. The evidence, however, is not
sufficiently robust and the most recent real-life data
(PATHOS study; [34]) showed difference in the efficacy
of fixed associations on intermediate endpoints. It can
be consequently stated that:
Statement 1
One of the most critical aspects of COPD and asthma is represented by the
diagnosis and identification of target patients. However, considering that COPD
and asthma are preventable diseases, it is important to invest resources not
only to improve the diagnostic phase, but also on prevention and, particularly,
on the recognition of risk factors. This requires the involvement of professionals,
especially General Practitioners (GPs), in tailored training programs.With respect
to the time of diagnosis, the most critical issues are: i) failure to distinguish
between COPD and asthma; and ii) rare use of the spirometer (for reasons
such as low utility attributed to the tool by patients and clinicians,
complexity of result interpretation, waiting time, and out-of-pocket expen-
ses).It is therefore necessary for healthcare organizations to invest in
initiatives aimed at promoting prevention and early diagnosis, through a
greater focus on risk factors, patient education, a multidisciplinary approach
to the diseases and equity of access to services.Specifically there is need for: i)
a shift from the prevalent model of watchful waiting to more proactive
approaches to identify patients potentially at risk; ii) training for GPs and
other health professionals, with specific reference to GOLD, GINA and BTS
clinical guidelines among others [29–31] and the opinions of national
scientific societies regarding risk factors (particularly tobacco smoke) and
the use of the spirometer for a correct diagnosis and follow-up; iii) de-
velopment and spread of the use of informatics tools to analyze the
issue in terms of population data, in order to improve organizational planning
and analysis of standards of assistance for different categories of patients; and
iv) educational initiatives for patients, who often underestimate the importance
of these diseases and do not pay attention to symptoms.
Statement 2
During the diagnostic and therapeutic path of the patient with COPD or
asthma, the most critical moment is the one of disease staging for the
purposes of appropriate drug prescription or other therapeutic
interventions. The staging process needs to include an effective
management of co-morbidities and symptoms.Healthcare organizations
should invest in actions aimed at the improvement of early staging of
patients, in order to allow an efficient allocation of resources. Staging first
requires a correct execution of pulmonary function tests and particularly of
spirometry, conducted periodically and with the collaboration of different
professional figures (pulmonologist, GP, nurse operating in primary care)
to guarantee easier access to the test and correct interpretation of the
results. Healthcare organizations can exercise organizational planning
and control on this issue, requesting periodic reports from physicians
without this translating into an excessive bureaucratic burden.
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The literature has already compared survival outcomes
between patients taking fixed combinations of cortico-
steroids administered by inhalation and LABA, and fixed
combinations of corticosteroids administered by inhal-
ation and short-acting muscarinic antagonist (SAMA) in
patients with COPD. The data demonstrated superior
survival outcomes for the former treatments over the
latter [35]. A rather more recent study (trial TORCH;
[36]) shows that a fixed salmeterol/fluticasone associ-
ation does not result in a statistically significant reduc-
tion in mortality when compared to monotherapies or
placebo. The evidence on mortality cannot be deemed
sufficiently robust to draw conclusions on survival differ-
entials. We can therefore conclude that:
Adherence to therapy is also fundamental for the opti-
mal management of chronic respiratory diseases and to
avoid the waste of resources. Several studies show the
negative impact of low adherence to therapy on morbid-
ity and mortality rates, number of hospitalizations, and
spending, which is higher in the case of low adherence
with therapies [36–38]. Consequently:
Given the strict inclusion/exclusion criteria of patients
in clinical trials and in the study design, there are issues
that are left unanswered by registration studies in the
area of respiratory diseases. Some of these questions in-
clude: What is the real efficacy and safety of the treat-
ments available in different patient subgroups? What is
the effect of prolonged exposure to therapy? What is the
real adherence rate? For this reason:
Finally, given that evidence from certain studies could
not be generalizable to other populations, due to phar-
macogenomic differences, differences in settings and
clinical therapeutic pathways in which new drugs are in-
troduced, we could say that:
Discussion and conclusions
This study attempted to identify the most critical aspects
of COPD and asthma treatment and discuss the extent
to which current managerial and policy approaches can
Statement 3
Given the evidence published to date, fixed associations of ICS/LABA
available on the market for asthma and COPD present “no proof of
difference”, at least with respect to the clinical outcomes found during
registration trials, meaning surrogate endpoints (e.g. FEV1 at 24 h after
administration). The evidence is however insufficiently robust to be able to
confirm the presence of therapeutic equivalence between these drugs. More
recent real-life studies (e.g. PATHOS study, [34]) show instead a difference
between fixed associations when looking at intermediate endpoints
(number of exacerbations and hospitalizations).
Statement 4
Given that pharmaceutical treatment for COPD is primarily aimed at the
reduction of dyspnea to improve patients’ quality of life, and not to reduce
mortality, there is no available evidence regarding the impact of different
fixed associations on patients’ mortality. The TORCH trial [36] has missed
the statistical significance on the primary outcome of mortality. The
availability of such data would, however, be important for therapeutic
decision-making.
Statement 5a
A most critical aspect of treatment for COPD and asthma is the adherence
to therapeutic treatments. Data from the literature show a real-life adher-
ence between 10 and 40 %, versus 70 to 90 % in trials [39]. Higher
adherence to therapeutic treatments can be achieved through educational
and training activities, addressed to patients and caregivers, regarding the
disease characteristics and device use [40–43]. Additional factors that can
impair adherence are polytherapy, frequent administration, degree of
perception of benefits and adverse events. Therefore, it would be appropriate to
activate programs to monitor prescriptions and the use of therapy that allow
intervention with patients showing poor adherence to
treatments.Statement 5bPoor adherence is among the factors affecting the
acutization of COPD exacerbations and poor management of asthma.
Statement 6
For currently-available treatments as well as drugs in
development, it is important to collect real-life evidence on their overall
effects (clinical and economic) and, in particular, on the elements that
affect adherence to therapy. Among these, a number of factors are of
particular relevance: i) the number of drugs taken and frequency of
administration; ii) the type of device used; and iii) the level of knowledge
and education of the patient and the relationship s/he has with the
physician.Real life evidence on adherence and the contribution of
individual factors (specifically, the type of device used) can be gathered
through observational studies, both prospective and retrospective, possible
on a large scale, to be able to conduct analyses on homogeneous
subgroups. Such studies can be conducted by GPs in cooperation with
specialists, and using existing databases, on the condition that data cover
a large portion of the Italian national territory and that the data are
comprehensive and of good quality. Studies of this type conducted in the
Italian context have for instance provided relevant insights on critical aspects
effective management of asthma and COPD, pinpointing the problem of
inhaler mishandling in real-life settings [44 ,45].
Statement 7
For a disease such as COPD, pragmatic trials are potentially useful to collect
evidence as a proxy to real-life relevant endpoints. These studies allow for
maximization of the generalizability of results and their applicability to clinical
practice, which is particularly relevant for a complex disease like COPD, which
often occurs with several co-morbidities.
Statement 8
Whenever problems of transferability of results from international studies
are found, it is necessary to plan studies in the Italian context, in
particular real-life studies. These analyses would allow for an evaluation
of the epidemiological profile of patients affected, documentation of the
diagnostic approach and evaluation of the treatment strategies and
pathways followed.
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be improved. The results of the Delphi research high-
light which information and actions are deemed relevant
by clinicians and policy makers for an appropriate and
effective evaluation of incoming treatment options. This
has important implications for the stakeholders involved,
who could benefit from these findings for the identifica-
tion of critical information helpful for the effective evalu-
ation of new treatments. The discussion of the critical
steps in managing patients with these diseases allows clini-
cians, policy-makers and managers to identify priorities of
intervention, and the industry to be able to offer sup-
portive services addressing key concerns in the thera-
peutic decision process.
Panelists’ agreement on statements was very high from
the very beginning of the Delphi Study. This may reflect
a generalizable common view of payers (at regional and
local levels) and clinicians on the two major topics in-
vestigated, i.e., information needs regarding drugs and
clinical pathways. In addition, no significant differences
were observed between subgroups of experts depending
on their background.
There was, first, a general consensus that there is no
proof of difference among the existing therapeutic al-
ternatives, even if more recent real-world data show
differential effects of drugs at intermediate endpoints
(exacerbations and hospitalizations). Panelists also stressed
that there is no evidence on mortality and that the avail-
ability of such evidence could support decisions on drug
comparison and better resource allocation. Despite their
complexity, pragmatic trials were considered very useful
for collecting information that may be considered a proxy
of real-world evidence.
From a managerial viewpoint, actions on risk factors,
appropriate diagnosis, and patient staging were consid-
ered the most critical aspects. Local payers have empha-
sized the importance of a multidisciplinary approach to
staging and treatment, through the cooperation of differ-
ent healthcare professionals, while the importance of
preventive medicine and early diagnosis through careful
monitoring of higher risk patients was highlighted by cli-
nicians. As a consequence, initiatives aimed at proactively
identifying patients potentially at risk, training programs,
especially for GPs (but within a multi-disciplinary ap-
proach), and educational initiatives for patients, were
identified as the primary targets of public investments.
Adherence to therapy was also considered a critical issue.
Panelists highlighted that the frequency of drug adminis-
tration, device use, polytherapy and drug safety profiles
may strongly influence adherence. For this reason, they
advocate for real-world evidence on adherence that should
integrate data on drug risk-benefit profiles.
All these recommendations are useful both for
payers, if they want to pursue efficiency in resource al-
location, and for the industry, if it wants to
appropriately integrate data available at market launch
with post-marketing evidence and support payers’ ini-
tiatives to promote a better management of clinical
pathways.
Additional file
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